Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 1 Interventional Results available

PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors

ClinicalTrials.gov ID: NCT03284723

Public ClinicalTrials.gov record NCT03284723. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 4:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Dose Escalation Study Evaluating the Safety and Tolerability of PF-06804103 in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive and Negative Solid Tumors

Study identification

NCT ID
NCT03284723
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 1
Lead sponsor
Pfizer
Industry
Enrollment
95 participants

Conditions and interventions

Interventions

  • PF-06804103 Drug
  • PF-06804103 + Palbociclib +Letrozole Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2017
Primary completion
Aug 30, 2021
Completion
Aug 30, 2021
Last update posted
Sep 2, 2024

2017 – 2021

United States locations

U.S. sites
26
U.S. states
6
U.S. cities
17
Facility City State ZIP Site status
Banner-University Medical Center Tucson Tucson Arizona 85719
The University of Arizona Cancer Center - North Campus Tucson Arizona 85719
The University of Arizona Cancer Center Tucson Arizona 85724
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute Los Angeles California 90048
UCLA Health (main campus) Los Angeles California 90095
UCLA Hematology/Oncology Los Angeles California 90095
Santa Monica - UCLA Medical Center and Orthopaedic Hospital Santa Monica California 90404
UCLA Dept of Medicine - Hematology/Oncology, Santa Monica Santa Monica California 90404
UCLA Health, Santa Monica Santa Monica California 90404
Northside Hospital Inc.- GCS/Athens Athens Georgia 30606
Atlanta Cancer Care - Atlanta Atlanta Georgia 30342
Northside Hospital, Inc. - GCS/Northside Atlanta Georgia 30342
Northside Hospital Atlanta Georgia 30342
Northside Hospital,Inc.-GCS /Blairsville Blairsville Georgia 30512
Northside Hospital, Inc. - GCS/Canton Canton Georgia 30114
Atlanta Cancer Care - Cumming Cumming Georgia 30041
Northside Hospital, Inc.-GCS/Stemmer Decatur Georgia 30033
Suburban Hematology-Oncology Associates - Duluth Duluth Georgia 30096
Atlanta Cancer Care - Lake Spivey Jonesboro Georgia 30236
Suburban Hematology-Oncology Associates- Lawrenceville Lawrenceville Georgia 30046
Northside Hospital, Inc. - GCS/Macon Macon Georgia 31217
Northside Hospital, Inc. GCS/Kennestone Marietta Georgia 30060
Oncology Hematology West, PC dba Nebraska Cancer Specialists Omaha Nebraska 68130
The University of Texas MD Anderson Cancer Center Houston Texas 77030
University of Utah, Huntsman Cancer Hospital Salt Lake City Utah 84112
University of Utah, Huntsman Cancer Institute Salt Lake City Utah 84112

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03284723, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 2, 2024 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03284723 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →